Global Congestive Heart Failure Registry
Research type
Research Study
Full title
Global Congestive Heart Failure Registry (G-CHF)
IRAS ID
226240
Contact name
Patrick Donnelly
Contact email
Sponsor organisation
Bayer plc
Clinicaltrials.gov Identifier
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Heart failure is a rapidly increasing disease worldwide but there is no global HF study that documents demographics, socioeconomic factors, diagnostic and management patterns, causes, biomarkers, comorbidities, treatments, quality of life, barriers to care, and outcomes in all parts of the world. Such knowledge is essential in the prevention and treatment of this disease. This prospective global registry aims to help fill in these important gaps in the understanding of heart failure, and contribute to future interventions that can be applied worldwide.
20,000 – 25,000 patients will be enrolled over 5 years in sites located in North America, South America, Europe, Africa, Asia and the Middle East. Recruitment will occur in outpatient clinics or inpatient hospital wards of participating centres in both urban and rural, academic and community settings in each country, where feasible. Patients that are at least 18 years of age with a clinical diagnosis of heart failure are eligible for this study. Enrolled patients will be followed up for 2 years with a telephone visit at 6 and 18 months, and in-person visits at 12 and 24 months. At these time points, severity of symptoms, physical examination (at in-person visits), current medications, and clinical outcomes will be recorded.REC name
West Midlands - Solihull Research Ethics Committee
REC reference
17/WM/0278
Date of REC Opinion
10 Apr 2018
REC opinion
Further Information Favourable Opinion